French Population Study Reinforces Cardiovascular Risk Associated with mRNA COVID-19 Vaccines


TrialSite News

Recently, a team of researchers from France’s National Health Insurance program launched a population-wide study to investigate the risks of myocarditis and pericarditis due to COVID-19 vaccination.

Tapping into a suite of nationwide hospital discharge and vaccine databases, the group analyzed 1,612 cases of myocarditis and 1,613 cases of pericarditis identified in the European nation from May 12, 2021, to October 31, 2021. Conducting a retrospective matched case-control series studies, the team discovered the risk for both myocarditis and pericarditis spiked the first week after vaccination.

The increase in these cardiovascular-based adverse events increased even further after the second dose. Comparing both Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) mRNA vaccines, the study results, peer-reviewed and published in the journal Nature, indicate both mRNA vaccines introduce greater risk for myocarditis with the Moderna vaccine as compared to the Pfizer-BioNTech product.